Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ANAPTYSBIO, INC (ANAB)

AnaptysBio says post-trial briefing schedule set in Tesaro litigation

Neutral Impact 3 of 5 legal/regulatory Written later

AnaptysBio disclosed that the Court granted a joint stipulation setting the post-trial briefing schedule in its consolidated litigation with Tesaro and GlaxoSmithKline, following a trial held July 14-17, 2026. The filing contains no ruling on the merits, so the outcome of the dispute remains unresolved for shareholders.

Key points

  • Trial of the consolidated Tesaro litigation was held July 14-17, 2026.
  • The Court granted the parties' Joint Stipulation on July 28, 2026.
  • AnaptysBio's opening post-trial brief is due August 21, 2026, and post-trial argument is set for October 20, 2026.

The filing

CompanyANAPTYSBIO, INC (ANAB)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:05 PM ET
Accession number0001193125-26-326097

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.